Epistem offers highly sensitive and well characterised in vivo models of GI mucositis. These models can be used to assess potential mucositis therapies and to determine whether a novel therapeutic agent causes mucositis. These models provide physiological and histopathological evaluations of disease severity which can be used to determine the mechanism of action of a novel therapeutic agent and to define the optimum dosing regimen. To mimic a clinically relevant insult, total or partial body irradiation and chemotherapy agents can be administered.
The crypt cells affected by many chemotherapy agents are well characterised; the effects of novel mucositis agents on these cell populations can therefore be measured. This knowledge also enables the clinical consequences of novel oncology agents to be predicted.
GI Mucositis Model Description
The cytotoxic insult is administered and mucositis gradually develops. The effects on apoptosis and cell proliferation in a given cell population can be quantified within hours of irradiation. The effect on ulceration and diarrhoea severity can be quantified over the following days.
- Diarrhoea duration and severity
- Histology and immunohistochemistry
- Crypt survival
- Apoptosis and proliferation
- Multiplex analysis of inflammatory cytokines